305 related articles for article (PubMed ID: 35463360)
21. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
22. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.
Nagano T; Tachihara M; Nishimura Y
Cells; 2018 Nov; 7(11):. PubMed ID: 30445769
[TBL] [Abstract][Full Text] [Related]
25. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
26. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
27. The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ; Kim DS; Hoon Sung Y; Kim DH; Im K; Lee H; Lee CW; Cho J; Min J; Woo DC; Kim SE; Lee S; Kong YJ; Ryu HC; Kim JS; Rengasamy R; Ji W; Choi CM; Lee JC; Rho JK
Cancer Res; 2022 Jun; ():. PubMed ID: 35700239
[TBL] [Abstract][Full Text] [Related]
28. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Minari R; Bordi P; Tiseo M
Transl Lung Cancer Res; 2016 Dec; 5(6):695-708. PubMed ID: 28149764
[TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Lim SM; Syn NL; Cho BC; Soo RA
Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
[TBL] [Abstract][Full Text] [Related]
30. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.
Tamiya M; Tamiya A; Okamoto N; Taniguchi Y; Nishino K; Atagi S; Hirashima T; Imamura F; Kumagai T; Suzuki H
Sci Rep; 2021 May; 11(1):9629. PubMed ID: 33953280
[TBL] [Abstract][Full Text] [Related]
31. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
32. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
33. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
35. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
Russo A; Franchina T; Ricciardi GRR; Smiroldo V; Picciotto M; Zanghì M; Rolfo C; Adamo V
Crit Rev Oncol Hematol; 2017 Sep; 117():38-47. PubMed ID: 28807234
[TBL] [Abstract][Full Text] [Related]
36. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
37. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.
Friese-Hamim M; Bladt F; Locatelli G; Stammberger U; Blaukat A
Am J Cancer Res; 2017; 7(4):962-972. PubMed ID: 28469968
[TBL] [Abstract][Full Text] [Related]
38. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.
Koulouris A; Tsagkaris C; Corriero AC; Metro G; Mountzios G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884398
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.
Masuzawa K; Yasuda H; Hamamoto J; Nukaga S; Hirano T; Kawada I; Naoki K; Soejima K; Betsuyaku T
Oncotarget; 2017 Dec; 8(62):105479-105491. PubMed ID: 29285266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]